Tuesday, April 23, 2024 4/23/2024

Defining the impact of dolutegravir on the maternal metabolic environment and its implications on risk of congenital anomalies.

Award Number: R01HD104553
ORGANIZATION: NATIONAL INSTITUTE OF CHILD HEALTH AND HUMAN DEVELOPMENT
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

Group Awards By Issue Date FY or Funding FY:

View Award Abstract

PROJECT SUMMARY/ABSTRACT: Dolutegravir (DTG)-based antiretroviral therapy (ART) is recommended by the World Health Organization for all people living with HIV, including pregnant women. Surveillance data from Botswana reported a 3-fold increased incidence of neural tube defects (NTDs) in women taking DTG from conception. Other studies have not detected this association although none were sufficiently powered. Concern over the clinical significance of the association between DTG and NTDs has created uncertainty in the treatment of women with HIV globally. Data from animal DTG fetotoxicity studies in our lab support the Botswana findings and suggest that DTG at a dose yielding clinically relevant plasma levels (1x-DTG) is associated with a modest but significantly increased risk of a variety of congenital defects including NTDs. Unexpectedly, we observe fewer fetal anomalies (similar to control) in mice treated with a 5x-DTG dose. Maternal folate deficiency, pre-gestational diabetes, and pre- pregnancy obesity are established NTD risk factors. Excessive weight gain is reported in persons initiating or switching to DTG. Excess weight gain and the underlying metabolic alterations could be a mechanism by which DTG increases NTD rates. We will use well-controlled animal studies and clinical samples from Botswana to perform an unbiased omics approach to identify potential pathways through which DTG may induce fetal defects. In addition, we will take a targeted approach, involving murine in vivo and embryo culture models, to investigate the impact of DTG on folate, glucose, and oxidative stress as potential pathways leading to DTG- associated fetal defects. In Aim 1 we will identify and validate maternal and fetal metabolic factors modified by DTG exposure that increase or reduce the risk for NTDs and other fetal anomalies by: (1) performing a metabolomics screen of pregnant mice and their fetuses treated with DTG-based ART (1x-DTG and 5x-DTG) or control for indicators of fetal anomaly risk or protection; (2) screening for metabolic differences in pregnant women with HIV on DTG-based ART from conception, compared with those on efavirenz-based ART from conception, and with HIV-negative pregnant women; (3) validating candidate metabolites using murine in vivo and embryo culture systems. In Aim 2 we will perform experimental studies to determine the mechanism(s) by which DTG increased the risk of fetal anomalies. We will examine the impact of DTG on: (1) folate metabolism; (2) glucose homeostasis; (3) oxidative stress and mitochondrial function, using murine in vivo and embryo culture systems. We will leverage resources of an existing prospective pregnancy study in Botswana (NIH/NICHD K23 HD088230-01A1 – PI: Dr. Zash), and take advantage of Dr. Serghides' robust mouse pregnancy model of ART safety, Drs. Copp and Greene's renowned expertise in models of NTDs, and the omics expertise of Metabolon, Dr. Jao, and Dr. Coburn to successfully complete this project. Our study will be the first to examine associations between DTG and metabolic alterations as a mechanism underlying DTG- associated congenital defects.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2023 ( Subtotal = $263,042 )
2023	2023	UNIVERSITY HEALTH NETWORK	200 ELIZABETH ST	TORONTO	ON			CAN	Child Health and Human Development Extramural Research	000	4	5/12/2023	NON-COMPETING CONTINUATION	$263,042
														Subtotal = $263,042

Issue Date FY: 2022 ( Subtotal = $321,745 )
2022	2022	UNIVERSITY HEALTH NETWORK	200 ELIZABETH ST	TORONTO	ON			CAN	Child Health and Human Development Extramural Research	000	3	7/1/2022	NON-COMPETING CONTINUATION	$321,745
														Subtotal = $321,745

Issue Date FY: 2021 ( Subtotal = $353,285 )
2021	2021	UNIVERSITY HEALTH NETWORK	200 ELIZABETH ST	TORONTO	ON			CAN	Child Health and Human Development Extramural Research	002	2	8/27/2021	NON-COMPETING CONTINUATION	$7,066
2021	2021	UNIVERSITY HEALTH NETWORK	200 ELIZABETH ST	TORONTO	ON			CAN	Child Health and Human Development Extramural Research	001	2	6/28/2021	NON-COMPETING CONTINUATION	$346,219
2021	2020	UNIVERSITY HEALTH NETWORK	200 ELIZABETH ST	TORONTO	ON			CAN	Child Health and Human Development Extramural Research	000	1	11/4/2020	NEW	$0
														Subtotal = $353,285

Issue Date FY: 2020 ( Subtotal = $278,390 )
2020	2020	UNIVERSITY HEALTH NETWORK	200 ELIZABETH ST	TORONTO	ON	M5G 2C4		CAN	Child Health and Human Development Extramural Research	000	1	9/21/2020	NEW	$278,390
														Subtotal = $278,390

Grand Total All Awards = $1,216,462

Top

All Categories

About

Search

Reports

Data Submission

Award Information

Defining the impact of dolutegravir on the maternal metabolic environment and its implications on risk of congenital anomalies.

Award Number: R01HD104553

ORGANIZATION: NATIONAL INSTITUTE OF CHILD HEALTH AND HUMAN DEVELOPMENT

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer